Share on StockTwits

OHR Pharmaceutical (NASDAQ:OHRP) Director Ira A. Greenstein bought 1,000 shares of the stock on the open market in a transaction dated Wednesday, July 2nd. The shares were purchased at an average cost of $8.40 per share, with a total value of $8,400.00. Following the acquisition, the director now directly owns 456,496 shares of the company’s stock, valued at approximately $3,834,566. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of OHR Pharmaceutical (NASDAQ:OHRP) traded down 2.99% during mid-day trading on Friday, hitting $8.12. 587,796 shares of the company’s stock traded hands. OHR Pharmaceutical has a 52 week low of $5.65 and a 52 week high of $20.00. The stock has a 50-day moving average of $8.83 and a 200-day moving average of $10.93. The company’s market cap is $191.8 million.

Separately, analysts at Brean Capital raised their price target on shares of OHR Pharmaceutical from $21.00 to $34.00 in a research note on Tuesday, June 24th. They now have a “buy” rating on the stock.

Ohr Pharmaceutical Inc (NASDAQ:OHRP) is a biotechnology rollup company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.